More than half of lung adenocarcinoma cases (most common subtype of non-small cell lung cancer) have an identifiable molecular driver. These are also referred to as "biomarkers." 

Biomarkers can tell us what is inside the cancer cells that might be driving the tumor's growth. There are currently at least 10 known biomarkers in non-small cell lung cancer for which patients may be tested. 2 of these biomarkers are associated with approved therapies: